Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16632764 | 0.97 | DGAT1 (0.48) | DGAT1USP2SMN1; SMN2CA1CA2 | |
| SCHEMBL320271 | 0.82 | DGAT1 (0.50) | DGAT1USP2SMN1; SMN2CA1CA2 | |
| SCHEMBL27747511 | 0.82 | DGAT1 (0.50) | DGAT1USP2SMN1; SMN2CA1CA2 | |
| Hydrochloric Acid SCHEMBL485921 | 0.80 | DGAT1 (0.48) | DGAT1USP2SMN1; SMN2CA1CA2 | |
| SCHEMBL10892362 | 0.80 | DGAT1 (0.48) | DGAT1USP2SMN1; SMN2CA1CA2 | |
| SCHEMBL1061233 | 0.80 | DGAT1 (0.48) | DGAT1USP2SMN1; SMN2CA1CA2 | |
| SCHEMBL4615927 | 0.78 | DGAT1 (0.46) | DGAT1ALDH1A1 | |
| SCHEMBL21058313 | 0.78 | DGAT1 (0.46) | DGAT1SMN1; SMN2CA1CA2BCHE | |
| SCHEMBL26085509 | 0.78 | DGAT1 (0.46) | DGAT1 | |
| SCHEMBL19924974 | 0.78 | DGAT1 (0.46) | DGAT1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3548096-B1 | INHIBITOR-FUNCTIONALIZED ULTRASMALL NANOPARTICLES AND METHODS THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240082417-A1 | PROTEIN-POLYMER DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2024-03-14 | — | — | US | disclosed |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2023-06-15 | — | — | US | disclosed |
| US-11660354-B2 | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-05-30 | — | — | US | disclosed |
| US-11434278-B2 | Protein-polymer-drug conjugates | ASANA BIOSCIENCES, LLC (US) | 2022-09-06 | — | — | US | disclosed |
| US-20210115491-A1 | Assay for High-Throughput Identification of Therapeutic Compounds | Middle Tennessee State University (US) | 2021-04-22 | — | — | US | disclosed |
| US-10851400-B2 | Assay for high-throughput identification of therapeutic compounds | BICKER KEVIN L (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3548096-A1 | INHIBITOR-FUNCTIONALIZED ULTRASMALL NANOPARTICLES AND METHODS THEREOF | Memorial Sloan Kettering Cancer Center (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190282712-A1 | INHIBITOR-FUNCTIONALIZED ULTRASMALL NANOPARTICLES AND METHODS THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER | 2019-09-19 | — | — | US | disclosed |
| CN-110167601-A | Inhibitor-small nanoparticle of functionalization ultra micro and its method | 纪念斯隆凯特琳癌症中心 | 2019-08-23 | — | — | CN | disclosed |
| WO-2004074335-A1 | NOVEL CATIONIC POLYMERS AND COPOLYMERS, USE THEREOF FOR THE VECTORISATION OF BIOMOLECULES AND SYNTHETIC INTERMEDIATES FOR THE SAME | HALISOL (FR) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074336-A1 | NOVEL CATIONIC COPOLYMERS, USE THEREOF FOR THE VECTORISATION OF BIOMOLECULES AND SYNTHETIC INTERMEDIATES FOR THE SAME | HALISOL (FR) | 2004-09-02 | — | — | WO | disclosed |
| CN-1140511-C | As integrin alphavβ3Aminopiperidine derivatives as antagonists | �����Ƹ���ʽ���� | 2004-03-03 | — | — | CN | disclosed |
| EP-1094812-A4 | ANGIOGENESIS INHIBITORS | SCRIPPS RESEARCH INST (US) | 2003-04-16 | — | — | EP | disclosed |
| EP-0761681-B1 | Process for the preparation of substituted derivatives of N-ethylglycine | HOECHST AG (DE) | 2002-03-13 | — | — | EP | disclosed |
| EP-1094812-A1 | ANGIOGENESIS INHIBITORS | The Scripps Research Institute (US) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000001383-A1 | ANGIOGENESIS INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2000-01-13 | — | — | WO | disclosed |
| US-5817811-A | AMIDATION OF THE CORRESPOND ESTERIFIED AMINE COMPOUND WITH A CARBOXYLATED NUCLEOTIDE BASE | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-10-06 | — | — | US | disclosed |
| CN-1159196-A | Inhibitors of interleukin-1'beta' converting enzyme | VERTEX PHARMA (US) | 1997-09-10 | — | — | CN | disclosed |
| EP-0761681-A2 | Process for the preparation of substituted derivatives of N-ethylglycine | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115491-A1 | Assay for High-Throughput Identification of Therapeutic Compounds | BACE1, FURIN, BACE2 | DGAT1 3501/4885USP2 1510/4885SMN1; SMN2 488/4885 |
| US-10851400-B2 | Assay for high-throughput identification of therapeutic compounds | BACE1, FURIN, BACE2 | DGAT1 3501/4885USP2 1510/4885SMN1; SMN2 488/4885 |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | DGAT1 4700/4885USP2 1180/4885SMN1; SMN2 2729/4885 |
| US-11660354-B2 | Inhibitor-functionalized ultrasmall nanoparticles and methods thereof | GRPR, GIPR, PSMA1 | DGAT1 3885/4885USP2 449/4885SMN1; SMN2 4032/4885 |
| US-11434278-B2 | Protein-polymer-drug conjugates | PBRM1, STAMBP, TSPO | DGAT1 4700/4885USP2 1180/4885SMN1; SMN2 2729/4885 |
| US-20240082417-A1 | PROTEIN-POLYMER DRUG CONJUGATES | PBRM1, STAMBP, TSPO | DGAT1 4688/4885USP2 1140/4885SMN1; SMN2 2874/4885 |
| US-20190282712-A1 | INHIBITOR-FUNCTIONALIZED ULTRASMALL NANOPARTICLES AND METHODS THEREOF | GRPR, GIPR, PSMA1 | DGAT1 3885/4885USP2 449/4885SMN1; SMN2 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.